scholarly journals Treatment (tx) patterns in patients (pts) with lung cancer starting 1st or 2nd generation (1G/2G) EGFR-TKI: A US insurance claims database analysis

2018 ◽  
Vol 29 ◽  
pp. ix156-ix157 ◽  
Author(s):  
J.E. Gray ◽  
B. Thakrar ◽  
P. Sun ◽  
S. Maclachlan ◽  
N. Chehab ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Insurance Claims ◽  
Database Analysis ◽  
Claims Database ◽  
2Nd Generation ◽  
Egfr Tki

scholarly journals Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis

2021 ◽  
Author(s):  
Jared Silver ◽  
Nestor Molfino ◽  
Michael Bogart ◽  
Elizabeth R. Packnett ◽  
Donna McMorrow ◽  
...  
Keyword(s):  
Real World ◽  
Insurance Claims ◽  
Database Analysis ◽  
Claims Database ◽  
Life Threatening

scholarly journals EP1.01-72 Treatment Outcome of 2nd Generation EGFR-TKI for Non-Small Cell Lung Cancer

2019 ◽  
Vol 14 (10) ◽  
pp. S939-S940
Author(s):  
T. Kondo ◽  
Y. Nakahara ◽  
R. Usui ◽  
S. Murakami ◽  
T. Kato ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Treatment Outcome ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
2Nd Generation ◽  
Egfr Tki

Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis

2016 ◽  
Vol 219 ◽  
pp. 387-393 ◽  
Author(s):  
Patrick Blin ◽  
François Philippe ◽  
Stéphane Bouée ◽  
Caroline Laurendeau ◽  
Elodie Torreton ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Insurance Claims ◽  
Database Analysis ◽  
Claims Database

scholarly journals Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis

2017 ◽  
Vol 2 (2) ◽  
pp. 209-219 ◽  
Author(s):  
Bernard Charbonnel ◽  
Dominique Simon ◽  
Jean Dallongeville ◽  
Isabelle Bureau ◽  
Sylvie Dejager ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Medical Costs ◽  
Insurance Claims ◽  
Database Analysis ◽  
Claims Database ◽  
Direct Medical Costs

Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers

2019 ◽  
Vol 19 (23) ◽  
pp. 2128-2142 ◽  
Author(s):  
Hao He ◽  
Chang Xu ◽  
Zhao Cheng ◽  
Xiaoying Qian ◽  
Lei Zheng
Keyword(s):  
Lung Cancer ◽  
Adjuvant Therapy ◽  
Combination Therapy ◽  
Clinical Benefit ◽  
Poor Prognosis ◽  
Egfr Mutations ◽  
Kras Mutations ◽  
Lung Cancers ◽  
Egfr Tki ◽  
Egfr Tkis

: KRAS is the most common oncogene to be mutated in lung cancer, and therapeutics directly targeting KRAS have proven to be challenging. The mutations of KRAS are associated with poor prognosis, and resistance to both adjuvant therapy and targeted EGFR TKI. EGFR TKIs provide significant clinical benefit for patients whose tumors bear EGFR mutations. However, tumors with KRAS mutations rarely respond to the EGFR TKI therapy. Thus, combination therapy is essential for the treatment of lung cancers with KRAS mutations. EGFR TKI combined with inhibitors of MAPKs, PI3K/mTOR, HDAC, Wee1, PARP, CDK and Hsp90, even miRNAs and immunotherapy, were reviewed. Although the effects of the combination vary, the combined therapeutics are one of the best options at present to treat KRAS mutant lung cancer.

Sign in / Sign up

Export Citation Format

Share Document